These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18848943)

  • 1. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.
    Gurrin LC; Osborne NJ; Constantine CC; McLaren CE; English DR; Gertig DM; Delatycki MB; Southey MC; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ;
    Gastroenterology; 2008 Dec; 135(6):1945-52. PubMed ID: 18848943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.
    Adams PC; Reboussin DM; Barton JC; Acton RT; Speechley M; Leiendecker-Foster C; Meenan R; Passmore L; McLaren CE; McLaren GD; Gordeuk V; Dawkins F; Eckfeldt JH
    Int J Lab Hematol; 2008 Aug; 30(4):300-5. PubMed ID: 18665827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.
    Allen KJ; Bertalli NA; Osborne NJ; Constantine CC; Delatycki MB; Nisselle AE; Nicoll AJ; Gertig DM; McLaren CE; Giles GG; Hopper JL; Anderson GJ; Olynyk JK; Powell LW; Gurrin LC;
    Hepatology; 2010 Sep; 52(3):925-33. PubMed ID: 20583211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study.
    McLaren CE; Barton JC; Gordeuk VR; Wu L; Adams PC; Reboussin DM; Speechley M; Chang H; Acton RT; Harris EL; Ruggiero AM; Castro O;
    Am J Hematol; 2007 Oct; 82(10):898-905. PubMed ID: 17597476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heritability of serum iron measures in the hemochromatosis and iron overload screening (HEIRS) family study.
    McLaren CE; Barton JC; Eckfeldt JH; McLaren GD; Acton RT; Adams PC; Henkin LF; Gordeuk VR; Vulpe CD; Harris EL; Harrison BW; Reiss JA; Snively BM
    Am J Hematol; 2010 Feb; 85(2):101-5. PubMed ID: 20095037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemochromatosis and iron-overload screening in a racially diverse population.
    Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
    N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the hemochromatosis gene in Italian candidate blood donors with increased transferrin saturation.
    Velati C; Marlianici E; Rigamonti D; Barillari G; Chiavilli F; Fugiani P; Garozzo G; Lancieri M; Rinaldi S; Testa D; Sampietro M; Tavazzi D; Delbini P; Fargion S; Fiorelli G
    Hematol J; 2003; 4(6):436-40. PubMed ID: 14671617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.
    Barton JC; Acton RT; Leiendecker-Foster C; Lovato L; Adams PC; McLaren GD; Eckfeldt JH; McLaren CE; Reboussin DM; Gordeuk VR; Speechley MR; Reiss JA; Press RD; Dawkins FW;
    Genet Test; 2007; 11(3):269-75. PubMed ID: 17949288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study.
    Adams PC; Pankow JS; Barton JC; Acton RT; Leiendecker-Foster C; McLaren GD; Speechley M; Eckfeldt JH
    Circ Cardiovasc Genet; 2009 Feb; 2(1):34-7. PubMed ID: 20031565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype-stratified cohort study of hemochromatosis in Australian women.
    Warne CD; Zaloumis SG; Bertalli NA; Delatycki MB; Nicoll AJ; McLaren CE; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ; Gurrin LC;
    J Gastroenterol Hepatol; 2017 Apr; 32(4):797-802. PubMed ID: 27784128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-overload-related disease in HFE hereditary hemochromatosis.
    Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
    N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.
    Ryan E; Ryan JD; Russell J; Coughlan B; Tjalsma H; Swinkels DW; Stewart S; Crowe JP
    Acta Haematol; 2015; 133(2):155-61. PubMed ID: 25277871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the HFE hemochromatosis gene in a community-based population of elderly women.
    Rossi E; Kuek C; Beilby JP; Jeffrey GP; Devine A; Prince RL
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1150-4. PubMed ID: 15377292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level.
    Yamashita C; Adams PC
    Clin Gastroenterol Hepatol; 2003 Sep; 1(5):388-91. PubMed ID: 15017658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemochromatosis mutations in the general population: iron overload progression rate.
    Andersen RV; Tybjaerg-Hansen A; Appleyard M; Birgens H; Nordestgaard BG
    Blood; 2004 Apr; 103(8):2914-9. PubMed ID: 15070663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 hemochromatosis and iron overload screening (HEIRS) study participants.
    Acton RT; Barton JC; Leiendecker-Foster C; Zaun C; McLaren CE; Eckfeldt JH
    Blood Cells Mol Dis; 2010 Apr; 44(4):252-6. PubMed ID: 20178892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis.
    Lawless MW; White M; Mankan AK; O'Dwyer MJ; Norris S
    Tissue Antigens; 2007 Oct; 70(4):294-300. PubMed ID: 17767550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular genetic diagnostics and screening of hereditary hemochromatosis].
    Zlocha J; Kovács L; Pozgayová S; Kupcová V; Durínová S
    Vnitr Lek; 2006 Jun; 52(6):602-8. PubMed ID: 16871764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.
    Gurrin LC; Bertalli NA; Dalton GW; Osborne NJ; Constantine CC; McLaren CE; English DR; Gertig DM; Delatycki MB; Nicoll AJ; Southey MC; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ;
    Hepatology; 2009 Jul; 50(1):94-101. PubMed ID: 19554541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study.
    Barton JC; Leiendecker-Foster C; Reboussin DM; Adams PC; Acton RT; Eckfeldt JH;
    Thyroid; 2008 Aug; 18(8):831-8. PubMed ID: 18651828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.